Study protocol for a Randomised controlled trial of EArly transjugular intrahepatiC porTosystemic stent-shunt in Acute Variceal Bleeding (REACT-AVB trial).
CIRRHOSIS
GASTROINTESTINAL BLEEDING
OESOPHAGEAL VARICES
PORTAL HYPERTENSION
STENTS
Journal
BMJ open gastroenterology
ISSN: 2054-4774
Titre abrégé: BMJ Open Gastroenterol
Pays: England
ID NLM: 101660690
Informations de publication
Date de publication:
22 Mar 2024
22 Mar 2024
Historique:
received:
02
12
2023
accepted:
16
02
2024
medline:
23
3
2024
pubmed:
23
3
2024
entrez:
22
3
2024
Statut:
epublish
Résumé
In liver cirrhosis, acute variceal bleeding (AVB) is associated with a 1-year mortality rate of up to 40%. Data on early or pre-emptive transjugular intrahepatic portosystemic stent-shunt (TIPSS) in AVB is inconclusive and may not reflect current management strategies. Randomised controlled trial of EArly transjugular intrahepatiC porTosystemic stent-shunt in AVB (REACT-AVB) aims to investigate the clinical and cost-effectiveness of early TIPSS in patients with cirrhosis and AVB after initial bleeding control. REACT-AVB is a multicentre, randomised controlled, open-label, superiority, two-arm, parallel-group trial with an internal pilot. The two interventions allocated randomly 1:1 are early TIPSS within 4 days of diagnostic endoscopy or secondary prophylaxis with endoscopic therapy in combination with non-selective beta blockers. Patients aged ≥18 years with cirrhosis and Child-Pugh Score 7-13 presenting with AVB with endoscopic haemostasis are eligible for inclusion. The primary outcome is transplant-free survival at 1 year post randomisation. Secondary endpoints include transplant-free survival at 6 weeks, rebleeding, serious adverse events, other complications of cirrhosis, Child-Pugh and Model For End-Stage Liver Disease (MELD) scores at 6 and 12 months, health-related quality of life, use of healthcare resources, cost-effectiveness and use of cross-over therapies. The sample size is 294 patients over a 4-year recruitment period, across 30 hospitals in the UK. Research ethics committee of National Health Service has approved REACT-AVB (reference number: 23/WM/0085). The results will be submitted for publication in a peer-reviewed journal. A lay summary will also be emailed or posted to participants before publication. ISRCTN85274829; protocol version 3.0, 1 July 2023.
Identifiants
pubmed: 38519049
pii: bmjgast-2023-001314
doi: 10.1136/bmjgast-2023-001314
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Matthew Armstrong
(M)
Andrew King
(A)
Faisal Khan
(F)
David Patch
(D)
Evangelia Fatourou
(E)
Jayshri Shah
(J)
Naaventhan Palaniyappan
(N)
Imran Patanwala
(I)
Jeremy Cobbold
(J)
Richard J Aspinall
(RJ)
Steven Masson
(S)
Teik Choon See
(TC)
Edward Britton
(E)
Syed Alam
(S)
Janisha Patel
(J)
Victoria J Appleby
(VJ)
Robert Driver
(R)
Laura Harrison
(L)
Ameet Dhar
(A)
James Maurice
(J)
Jude Morris
(J)
Adrian Stanley
(A)
Peter Hayes
(P)
Joanna Leithead
(J)
Ruairí Lynch
(R)
Tom Pembroke
(T)
Jagadish Nagaraj
(J)
Fidan Yousuf
(F)
Roger McCorry
(R)
Informations de copyright
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.